Three studies exploring interventions to improve the quality of life for patients with cancer will be highlighted in the 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium’s official Press Program. The interventions included yoga-based supportive care, a virtual mind-body fitness program, and a text-based e-triage system.
September 20, 2023
July 31, 2023
A combination of resistance and aerobic exercise may improve sexual function in patients with prostate cancer according to a new study conducted in Australia. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 31, 2023
Researchers in Japan developed an artificial intelligence (AI)-based diagnostic tool for colposcopy examinations that can accurately identify cervical intraepithelial neoplasia (CIN)—abnormal cells found on the surface of the cervix that may become cancer and spread to nearby normal tissue—and suggest appropriate biopsy sites. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 31, 2023
A new, multi-target stool DNA methylation assay accurately detected and identified the tissue of origin of multiple gastrointestinal (GI) cancers. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 31, 2023
A non-invasive blood test successfully detected early-stage cancer and identified tumor location in asymptomatic individuals in Vietnam according to a new study. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Breakthrough Meeting, taking place August 3-5 in Yokohama, Japan.
July 24, 2023
In patients with wild-type TP53 advanced or recurrent endometrial cancer, the addition of maintenance therapy with selinexor following systemic therapy may prolong progression-free survival (PFS), according to research that will be presented during the July 2023 session of the American Society of Clinical Oncology (ASCO) Plenary Series.
July 18, 2023
The American Society of Clinical Oncology (ASCO) Breakthrough Meeting will convene oncology professionals from around the world in Yokohama, Japan, to explore cutting-edge advances in cancer care technology and innovations that can help transform care for people living with cancer.
June 6, 2023
Twenty studies exploring a wide range of topics across many cancer disease sites will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, and online, June 2-6.
June 6, 2023
Results from the largest prospective study of primary mediastinal B-cell lymphoma show that radiation therapy can be omitted in patients who have a complete metabolic response after chemoimmunotherapy. The IELSG37 international study found that these patients may be spared from late toxicities without compromising the chances of cure. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2023
Trastuzumab deruxtecan (Enhertu®) is an effective treatment option for people with difficult-to-treat HER2-expressing solid tumors, according to the findings of an international study. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 5, 2023
Ciltacabtagene autoleucel (Carvykti®), a BCMA-targeting CAR T-cell therapy, significantly slows or stops progression of multiple myeloma when compared with standard-of-care treatments among those for whom lenalidomide no longer works. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
Treatment with osimertinib (Tagrisso®) after surgery significantly lowered the risk of death in adults with completely resected EGFR-mutated (EGFRm) stage IB, II, or IIIA non-small cell lung cancer (NSCLC), according to the findings of an international study. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
Vorasidenib, an oral dual inhibitor of mutant IDH1/2 enzymes, significantly improved progression-free survival in patients with grade 2 gliomas, a type of malignant brain tumor with poor long-term prognosis. This treatment delayed disease progression and was well-tolerated. These findings represent a significant step forward in the treatment of grade 2 glioma with IDH mutations. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
June 4, 2023
Patients with locally advanced rectal cancer with tumors that respond to chemotherapy can safely forego radiation therapy before surgery based on the findings of federally funded research that will be presented at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO) and simultaneously published in the New England Journal of Medicine (efficacy) and the Journal of Clinical Oncology (patient reported outcomes) on June 4, 2023. Omitting radiation therapy can reduce short- and long-term side effects that impact quality of life while providing similar outcomes in disease-free survival and overall survival.
June 2, 2023
Adding the targeted therapy drug ribociclib (Kisqali®) to hormonal (endocrine) therapy showed a significant improvement in invasive disease-free survival (iDFS) for people with HR-positive, HER2-negative early-stage breast cancer. The research will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Pages |